Patent US5798102A successfully refreshed from Google Patents.
US5798102A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Treatment of cardiomyopathy
Assignee: Milkhaus Laboratory Inc
•
Filing: 1997-03-04
•
Granted: 1998-08-25
•
Expires: 2017-03-04
Abstract
Abstract The invention presents methods for the treatment of symptoms associated with cardiomyopathy comprising treatment with an effective amount of a composition comprising beta-amyloid, streptolysin O, and growth hormone.
Inventors
- 👤 John McMichael
- 👤 Harry C. Gurney
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 12:15
CPC Classifications
A; A61; A61K; A61K38/00; A61K38/16; A61K38/17; A61K38/22; A61K38/27; A61P; A61P11/00; A61P3/00; A61P9/00
Claims Analysis
Total Claims: 14
Claim 1
Independent Claim
39 words
A composition for treatment of cardiomyopathy in humans comprising an effective amount of beta-amyloid, streptolysin O, and growth hormone wherein said amount of growth hormone is from about 1×10 -6 International Units to about 0.1 International Units per dose.
Claim 2
Dependent Claim
39 words
A composition for treatment of cardiomyopathy in humans comprising an effective amount of beta-amyloid, streptolysin O, and growth hormone wherein said amount of growth hormone is from about 1×10 -6 International Units to about 0.1 International Units per dose.
Claim 3
Dependent Claim
34 words
The composition according to claim 1 wherein said amount of beta-amyloid is from about 1×10 -11 mg to about 10 mg, and streptolysin O is from about 0.005 to about 50 units per dose.
Claim 4
Dependent Claim
32 words
The composition according to claim 1 wherein said amount of beta-amyloid is about 4×10 -9 mg, streptolysin O is 2 Units per dose, and growth hormone is 0.01 International Units per dose.
Claim 5
Dependent Claim
26 words
The composition according to claim 1 wherein said amount of growth hormone is from about 1×10 -6 International Units to about 0.01 International Units per dose.
Claim 6
Independent Claim
56 words
A method of ameliorating the symptoms of cardiomyopathy in humans comprising the step of administering from 1-10 drops per day to a patient diagnosed with cardiomyopathy an effective amount of beta-amyloid, streptolysin O, and growth hormone wherein said amount of growth hormone is from about 1×10 -6 International Units to about 0.1 International Units per dose.
Claim 7
Independent Claim
56 words
A method of ameliorating the symptoms of cardiomyopathy in humans comprising the step of administering from 1-10 drops per day to a patient diagnosed with cardiomyopathy an effective amount of beta-amyloid, streptolysin O, and growth hormone wherein said amount of growth hormone is from about 1×10 -6 International Units to about 0.1 International Units per dose.
Claim 8
Dependent Claim
34 words
The method according to claim 5, wherein said amount of beta-amyloid is from about 1×10 -11 mg to about 10 mg, and streptolysin O is from about 0.005 to about 50 units per dose.
Claim 9
Dependent Claim
28 words
The method according to claim 5 wherein said amount of beta-amyloid is about 4×10 -9 mg streptolysin O is 2 Units, and growth hormone is 0.01 International Units.
Claim 10
Dependent Claim
24 words
The method according to claim 5 wherein said growth hormone is from about 1×10 -6 International Units to about 0.01 Internal units per dose.
Claim 11
Dependent Claim
28 words
The method according to claim 5 wherein said composition is administered by a method selected for the group consisting of intramuscular, sublingual, intravenous, subctaneous, intrathecal, inhalation and topical.
Claim 12
Dependent Claim
12 words
The method according to claim 9 wherein said compound is administered sublingually.
Claim 13
Dependent Claim
11 words
The method of claim 9 wherein said compound is administered intravenously.
Claim 14
Dependent Claim
10 words
The composition of claim 1 in a pharmaceutically acceptable vehicle.
References Cited (Backward Citations)
US4294818A
Cited
US4521405A
Cited
US4704273A
Cited
US4705685A
Cited
US4880626A
Cited
US4666829A
Cited
US4816416A
Cited
US5187153A
Cited
US5223482A
Cited
US4912206A
Cited
WO1991016819A1
Cited
WO1995031996A1
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 2001-08-24 | 2002-02-23 | 2002-08-25 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 2005-08-24 | 2006-02-23 | 2006-08-25 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2009-08-24 | 2010-02-23 | 2010-08-25 | $7700.00 | Window Closed / Lapsed |